The company has faced a net loss of INR 641 Cr in FY'21 which is almost double the loss face by the company in FY'20. The higher net loss is a result of increased inventory purchased as well as higher employee remuneration expenses. Another reason is the constant discounted prices of pharmaceuticals, the burden of which has to be borne by the company.
The company has witnessed a massive revenue growth of 220% in FY'21 at INR 2,360 Cr. This is primarily due to the higher demand for pharmaceuticals and health care services due to the pandemic spreading all over the country.
EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ Cr
* denotes current year's data